Details of the Drug Combination

General Information of Drug Combination (ID: DC42ODQ)

Drug Combination Name

Amonafide Arfolitixorin

Indication

Disease Entry	Status	REF
Adult acute myeloid leukemia	Investigative	[1]

Component Drugs

Amonafide DMAH59S

Arfolitixorin DMIXMYK

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: HL-60(TB)

Zero Interaction Potency (ZIP) Score: 8.96

Bliss Independence Score: 8.61

Loewe Additivity Score: 9.29

LHighest Single Agent (HSA) Score: 11.83

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Anaplastic large cell lymphoma	DCW9VC2	SR	Investigative	[1]
Glioma	DCBQIM9	SF-268	Investigative	[1]
Large cell lung carcinoma	DCH6E61	NCI-H460	Investigative	[1]
Malignant melanoma	DCE28IS	LOX IMVI	Investigative	[1]
Carcinoma	DCGUCD8	RXF 393	Investigative	[4]
Colon adenocarcinoma	DC6KQ78	COLO 205	Investigative	[4]
Colon carcinoma	DCZLLFO	KM12	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DrugCom(s)

References

1	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
2	ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
4	CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165